CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T-Cell Activation at the Immunological Synapse.
Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T-Cell Activation at the Immunological Synapse.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞疗法已被证明是治疗血液系统恶性肿瘤的有效策略,但其针对实体瘤的持久性和活性仍需进一步改善。一种新兴的增强疗效策略基于将CAR-T 细胞导向抗原呈递细胞(APC)。在APC与T细胞之间形成的免疫突触(IS)处激活CAR-T 细胞被认为可促进强烈、持久的抗原特异性T细胞介导的免疫应答,但需要将CAR配体整合到APC/T细胞界面中。
在此,我们证明,含有神经节苷脂GM3的CAR配体功能化、脂质包被的可生物降解聚合物纳米颗粒(NPs)(GM3-NPs)可与表达CD169(Siglec-1)的APC结合,并在细胞结合物形成后定位于APC与CAR-T 细胞之间的细胞接触位点。CD169+ APC/CAR-T 细胞界面的特征为GM3-NPs与CARs的强烈光学共定位、F-actin富集以及ZAP-70募集,表明GM3-NPs整合到功能性IS中。与GM3-NPs相关的配体定位于APC/T细胞接触位点后仍可被CARs接触,并导致强烈的T细胞激活。
总体而言,本研究确定GM3-NPs是一种潜在的抗原递送平台,可用于主动靶向表达CD169的APC,并在含NP的IS处增强CAR-T 细胞激活。
Chimeric Antigen Receptor (CAR) T cell therapy has proven to be an effective strategy against hematological malignancies but persistence and activity against solid tumors must be further improved. One emerging strategy for enhancing efficacy is based on directing CAR T cells to antigen presenting cells (APCs).
Activation of CAR T cells at the immunological synapse (IS) formed between APC and T cell is thought to promote strong, persistent antigen-specific T cell-mediated immune responses but requires integration of CAR ligands into the APC/T-cell interface.
Here, we demonstrate that CAR ligand functionalized, lipid-coated, biodegradable polymer nanoparticles (NPs) that contain the ganglioside GM3 (GM3-NPs) bind to CD169 (Siglec-1)-expressing APCs and localize to the cell contact site between APCs and CAR T cells upon initiation of cell conjugates.
The CD169 + APC/CAR T-cell interface is characterized by a strong optical colocalization of GM3-NPs and CARs, enrichment of F-actin, and recruitment of ZAP-70, indicative of integration of GM3-NPs into a functional IS. Ligands associated with GM3-NPs localized to the APC/T-cell contact site remain accessible to CARs and result in robust T-cell activation.
Overall, this work identifies GM3-NPs as a potential antigen delivery platform for active targeting of CD169 expressing APCs and enhancement of CAR T-cell activation at the NP-containing IS.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。